• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Metacrine Inc.

    12/8/22 12:08:05 PM ET
    $MTCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTCR alert in real time by email
    SC 13D 1 doc1.htm NONE Schedule 13D


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. n/a )*

    Metacrine, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    59101E103

    (CUSIP Number)


    Braden Leonard,  BML Capital Management, LLC  65 E Cedar - Suite 2  Zionsville,  IN  46077  Phone : 3173442447

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)


    December 08, 2022

    (Date of Event which Requires Filing of this Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.    x

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    1
    NAMES OF REPORTING PERSONS
       
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
    BML Investment Partners, L.P.
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    o
     
    (b)
    x
       
    3
    SEC USE ONLY
       
         
       
    4
    SOURCE OF FUNDS
       
    WC
       
       
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f)
     
    o
     
       
       
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    Delaware
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
       
    0
       
       
    8
    SHARED VOTING POWER
       
    5888965
       
       
    9
    SOLE DISPOSITIVE POWER
       
    0
       
       
    10
    SHARED DISPOSITIVE POWER
       
    5888965
       
       
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    5888965
       
       
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
     
    o
     
       
       
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
    13.8%
       
       
    14
    TYPE OF REPORTING PERSON
       
    PN
       
       
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934.
     
    1
    NAMES OF REPORTING PERSONS
       
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
    Braden M Leonard
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    o
     
    (b)
    x
       
    3
    SEC USE ONLY
       
         
       
    4
    SOURCE OF FUNDS
       
    PF
       
       
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(e) or 2(f)
     
    o
     
       
       
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    United States
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
       
    600000
       
       
    8
    SHARED VOTING POWER
       
    5888965
       
       
    9
    SOLE DISPOSITIVE POWER
       
    600000
       
       
    10
    SHARED DISPOSITIVE POWER
       
    5888965
       
       
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    6488965
       
       
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
     
    o
     
       
       
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
    15.2%
       
       
    14
    TYPE OF REPORTING PERSON
       
    IN  PN
       
       
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Act.
     
     
     
    Item 1.
    Security and Issuer
      
     
     
    This statement relates to the common shares, $0.0001 par value (the “Common Stock”), of Metacrine, Inc. (the “Issuer”), having its principal executive office at 4225 Executive Square, Suite 600., San Diego, CA 92037.
     
    Item 2.
    Identity and Background
      
     
     
    (a)
    This statement is being filed by BML Investment Partners, L.P., a Delaware limited partnership, and Braden M. Leonard. BML Capital Management, LLC, an Indiana limited liability company, is the general partner to BML Investment Partners, L.P. Braden M. Leonard is the sole managing member of the general partner.

    BML Investment Partners, L.P. - The business address of BML Investment Partners, L.P. is 65 E Cedar – Suite 2, Zionsville, IN 46077. The principal business of BML Investment Partners, L.P. is to purchase, sell, trade and invest in securities.

    BML Capital Management, LLC - The business address of BML Capital Management, LLC is 65 E Cedar – Suite 2, Zionsville, IN 46077. The principal business of BML Capital Management, LLC is to serve as the general partner to BML Investment Partners, L.P.

    Braden M. Leonard – Mr. Leonard’s business address is 65 E Cedar – Suite 2, Zionsville, IN 46077. Mr. Leonard’s principal business is to serve as managing member of BML Capital Management, LLC.

     
    (b)
    65 E Cedar – Suite 2, Zionsville, IN 46077

     
    (c)
    The principal business of BML Investment Partners, L.P. is to purchase, sell, trade and invest in securities.

    The principal business of BML Capital Management, LLC, is to serve as the general partner to BML Investment Partners, L.P.

    Mr. Leonard’s principal business is to serve as managing member of BML Capital Management, LLC.

     
    (d)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     
    (e)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws

     
    (f)
    Braden M. Leonard is a citizen of the United States of America.
     
    Item 3.
    Source and Amount of Funds or Other Consideration
      
     
     
    BML Investment Partners, L.P. holds 5,888,965 shares of Common Stock which were acquired using working capital.

    Braden M. Leonard holds 600,000 shares of Common Stock which were acquired using
     
    Item 4.
    Purpose of Transaction
      
     
    The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

    The Reporting Persons plan to vote AGAINST the proposed merger with Equillium,Inc, unless the collar is adjusted to reflect the current Equillium share price.

    No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the board of directors of the Issuer (the “Board”), engaging in discussions with stockholders of the Issuer or third parties, including potential acquirers and service providers about the Issuer and the Reporting Persons’ investment, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, including an alternative sale of the Issuer as a whole or in parts, Board structure (including Board composition) or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item

     
    (a)
    See above.

     
    (b)
    See above.

     
    (c)
    See above.

     
    (d)
    See above.

     
    (e)
    See above.

     
    (f)
    See above.

     
    (g)
    See above.

     
    (h)
    See above.

     
    (i)
    See above.

     
    (j)
    See above.
     
    Item 5.
    Interest in Securities of the Issuer
      
     
    (a)
    As of Dec 8, 2022, BML Investment Partners owns 5,888,965 shares of the issuer, which represents 13.8% of the shares outstanding.

    As of Dec 8, 2022, Braden M Leonard owns 6,488,956 shares of the issuer, which represents 15.2% of the shares outstanding.

     
    (b)
    Mr. Leonard has sole voting power over 600,000 shares, sole dispositive power over 600,000 shares, shared voting power over 5,888,965 shares and shared dispositive power over 5,888,965 shares.

    BML Investment Partners, L.P. has sole voting power over 0 shares, sole dispositive power over 0 shares, shared voting power over 5,888,965 shares and shared dispositive power over 5,888,965 shares.

     
    (c)
    See below.

     
     
    Transaction Date Shares or Units Purchased (Sold) Price Per Share or Unit 
     
     
    09/08/2022
    10/24/2022
    10/25/2022
    10/26/2022
    10/27/2022
    10/28/2022
    11/07/2022
    11/08/2022
    11/09/2022
     150,000
    174,354
    499,279
    588,533
    767,507
    45,022
    123,954
    500
    39,816
     0.50
    0.35
    0.36
    0.36
    0.40
    0.41
    0.43
    0.41
    0.40
     

     
     

     
    (d)
    No.

     
    (e)
    N/A
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
      
     
     
    None.
     
    Item 7.
    Material to Be Filed as Exhibits
      
     
     
    None.
     

    Signature
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BML Capital Management, LLC
     
           
    December 08, 2022
    By:
    /s/ Braden M Leonard
     
       
    Managing Member
     
           
     
     
           
    December 08, 2022
    By:
    /s/ Braden M Leonard
     
       
     
           
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Footnotes: 
     
    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $MTCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTCR

    DatePrice TargetRatingAnalyst
    10/22/2021$2.50Outperform → Sector Perform
    RBC Capital Mkts
    10/22/2021$19.00 → $1.00Buy → Hold
    Canaccord Genuity
    10/22/2021$14.00 → $2.00Buy → Hold
    Jefferies
    10/22/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $MTCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Metacrine downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Metacrine from Outperform to Sector Perform and set a new price target of $2.50

      10/22/21 7:43:25 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Metacrine from Buy to Hold and set a new price target of $1.00 from $19.00 previously

      10/22/21 7:42:38 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Jefferies with a new price target

      Jefferies downgraded Metacrine from Buy to Hold and set a new price target of $2.00 from $14.00 previously

      10/22/21 7:42:07 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

      LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t

      12/23/22 4:01:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Reports Third-Quarter 2022 Results

      SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership

      11/14/22 4:38:48 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Klassen Preston

      4 - Metacrine, Inc. (0001634379) (Issuer)

      3/24/23 12:35:32 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:44:04 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:42:52 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Metacrine Inc.

      15-12G - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:29:55 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:28:02 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Metacrine Inc.

      S-8 POS - Metacrine, Inc. (0001634379) (Filer)

      3/23/23 4:34:58 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Metacrine Announces Resignation of Chief Medical Officer

      SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass

      12/27/21 8:00:00 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

      SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.   “We’re excited to welcome Julia as a new independent director,” commented Richard Heyman, Ph.D., Metacrine’s chairman. “She is an accomplished biopharmaceutical executive, with an established track record in building companies, business development, capital formation and strategic partnerships. Juli

      4/5/21 4:05:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/14/23 4:00:28 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/8/23 3:43:35 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Metacrine Inc.

      SC 13G - Metacrine, Inc. (0001634379) (Subject)

      12/19/22 4:00:11 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Financials

    Live finance-specific insights

    See more
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products